Compare AVX & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | CNSY |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 20.6M |
| IPO Year | 2020 | 2016 |
| Metric | AVX | CNSY |
|---|---|---|
| Price | $4.22 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | ★ 329.4K | 161.9K |
| Earning Date | 11-13-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.55 | 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | $2,340,811.00 | ★ $5,213,000.00 |
| Revenue This Year | $18,042.77 | N/A |
| Revenue Next Year | $12.21 | $414.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3348.10 | N/A |
| 52 Week Low | $0.35 | $1.49 |
| 52 Week High | $7.38 | $4.03 |
| Indicator | AVX | CNSY |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 38.01 |
| Support Level | $3.02 | $1.54 |
| Resistance Level | $6.25 | $1.96 |
| Average True Range (ATR) | 0.69 | 0.17 |
| MACD | -0.20 | 0.04 |
| Stochastic Oscillator | 7.05 | 26.19 |
AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.